Navigation Links
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ --

- Professor Desire Collen Will Remain as Chairman of the Board and Scientific Advisor

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces today that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer on September 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member of the Board of Directors of ThromboGenics. In the mean time, he will be invited to the Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors. This new structure ensures the continuity of ThromboGenics' senior management.

Dr. De Haes, 50, has considerable international experience across the biotechnology and healthcare sectors spanning more than 20 years. For the last 18 months, Dr. De Haes has been ThromboGenics' Chief Operating Officer overseeing the Company's daily operations. During this period, he has been a key member of the management team that has achieved a number of transforming milestones for ThromboGenics. These include initiating the clinical development of the Company's unique anti-cancer agent TB-403, and the subsequent development deal for potentially up to EUR500 million with Roche. Dr. De Haes has also been a major contributor to the development strategy of ThromboGenics' lead product, microplasmin, which the Company plans to advance into Phase III clinical trials in early 2009 for the treatment of a number of important eye diseases.

Prior to joining ThromboGenics, Dr. De Haes was Head of the Global Insulin Infusion Business at Roche Diagnostics in Bern, Switzerland, and a member of the Executive Commit
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
2. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
3. ThromboGenics N.V. - Business Update
4. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
5. ThromboGenics Announces 2007 Full Year Results
6. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
11. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... use, researchers at the National Institute of Standards and ... with the world,s darkest material‑a forest of carbon nanotubes ... part of the infrared spectrum., NIST will use the ... Nano Letters ,* to make precision laser power ...
... Mich., Aug. 18 NephRx Corporation today announced that ... orphan drug designation to its lead product NX001 for ... transplant recipients.  NX001 is a kidney growth factor peptide ... two animal models of acute renal failure.   ...
... Aug. 17 Spherix Incorporated (Nasdaq: SPEX ... and the metabolic syndrome, and a provider of technical ... pharmaceutical companies, today reported results for the three months ... Upcoming Highlights Pharmaceutical Development ...
Cached Biology Technology:Extreme darkness: Carbon nanotube forest covers NIST's ultra-dark detector 2NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function 2Spherix Announces Second Quarter 2010 Financial Results 2Spherix Announces Second Quarter 2010 Financial Results 3Spherix Announces Second Quarter 2010 Financial Results 4Spherix Announces Second Quarter 2010 Financial Results 5Spherix Announces Second Quarter 2010 Financial Results 6
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... bounty of sardine at a time that set the backdrop for ... decade the nets came up empty and the fishery collapsed. Where ... scientists at Scripps Institution of Oceanography at UC San Diego, the ... target. Publishing in the Proceedings of the National Academy ...
... "moderate" red tide this spring and summer, report NOAA-funded scientists ... of Maine. The "red tide" is caused by an alga ... cause paralytic shellfish poisoning (PSP). Red tide typically occurs ... This year,s outlook is similar to the 2012 red ...
... the semi-arid wheatbelt of Western Australia with their rich ... new research to improve the management of natural resources ... combine the latest ideas in computer science at The ... Australian environmental planners. Researchers from the University,s ...
Cached Biology News:Predictions of climate impacts on fisheries can be a mirage 2Researchers issue forecast for 'moderate' New England red tide in 2013 2Nottingham-Australia collaboration on environmental conservation of the future 2Nottingham-Australia collaboration on environmental conservation of the future 3
... Chromatography Data System (CDS) now provides ... chromatography data processing and reporting for ... LC. The companys innovative HPLC instrument ... benefits of Thermo Scientific Hypersil GOLD ...
...
... ABsolute QPCR SYBR Green Mixes are optimised for ... components necessary to perform Quantitative PCR, with the ... SYBR Green Mix contains optimal levels of active ... supplied in a proprietary reaction buffer that enables ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
Biology Products: